Home

Treatment resistance

Read time: 7 min

Congress highlights

Steps towards long-term maintenance treatment for psychiatric disorders

Around 21% of patients with schizophrenia achieve clinical recovery – a statistic that hasn...

Read time: 7 min

Satellite symposium

Long-acting antipsychotic treatment: Initiation and optimisation

In an Industry sponsored symposium titled “Optimising long-acting therapy use in...

Read time: 3 min

Congress highlights

Predicting antidepressant response – problems and promises

Precision medicine is a burgeoning field and has the potential to aid diagnosis and tailor...

Read time: 3 min

Congress highlights

Can deep brain stimulation treat schizophrenia?

Widespread successful use of deep brain stimulation (DBS) to treat neurological conditions, such as...

Read time: 3 min

Satellite symposium

Beyond symptom reduction and towards engagement with life

Enhancing engagement with life is a key target of treatment in MDD and extends beyond symptom...

Read time: 2 min

Congress highlights

Partial dopamine agonists: wide spectrum of activity and indications

Dopamine partial agonists decrease transmission when there is excess of the neurotransmitter, but...

Read time: 2 min

Congress highlights

Reconceptualising treatment-resistant depression as difficult-to-treat depression

Treatment-resistant depression is a concept that needs to be clinically re-defined to encompass a...

Read time: 2 min

Satellite symposium

Early onset schizophrenia needs patient-specific management

Early diagnosis and effective, well-tolerated treatment of early-onset schizophrenia are crucial to...

Depression, Bipolar

Read time: 3 min

Congress highlights

Identifying and managing major depressive disorder with mixed features

According to Rakesh Jain, one in five people with major depressive disorder (MDD) have at least...

Neurotoriun

Neurotorium is your new point of reference for educational content on psychiatry, neurology, and neuroscience.

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind Greece Continue to Progress in Mind South East Asia Continue to Progress in Mind Middle East & Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Japan RC Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Sweden Continue to Progress in Mind Finland Continue to Progress in Mind Ukraine Continue to Progress in Mind Belgium & Luxembourg Continue to Progress in Mind Switzerland Continue to Progress in Mind Germany Continue to Progress in Mind Austria

You are leaving Progress in Mind

Continue to

Cancel

Progress in Mind Belux

Accept Cancel

Login as a registered health care professional

Please enter your email to continue

Register as a health care professional

Please enter your email to continue

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intended for health care professionals.

All the information included in the Website is related to diseases, investigations and existing or potential treatment options and, therefore, directed to health professionals . The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country